Intended Use


PhiCal Test  is a FDA quantitative enzyme-linked immunoassay (ELISA) for detection of increased concentrations of calprotectin in stools as a consequence of disease in the gastrointestinal tract.

During septicaemia, plasma calprotectin levels will rise more rapidly than C-reactive protein since increased synthesis of the latter by the liver takes time, while calprotectin is pre-formed in the leukocytes. 



  • Anne Thjømøe

    Executive Chairman 


    Direct line: +47 97 73 37 51

  • Inge Dale

    M.D., Ph.D. Chief Medical Officer


    Direct line: +47 91 31 45 03

  • Anne Hancke Framstad

    Laboratory Quality Specialist


    Direct line: +47 92 01 14 91

  • Einar Mørk

    Dir. Operations


    Direct line: +47 47 28 55 61

  • Mona Schartum

    Production Manager


    Direct line: +47 93 22 73 63

  • Ingvild Haukø

    Sales- and Marketing Manager


    Direct line: +47 92 01 52 18

  • Ali Qamar

    Product Manager


    Direct line: +47 41 17 81 19

General Information

Fecal calprotectin in differential diagnosis of irritable bowel syndrome

Li XG, Lv YM, Gu F, Yang XL., Department of Gastroenterology, Peking University Third May 9, 2015

PhiCal Test FDA approved

The PhiCal Test has now been approved by the FDA for clinical use in the USA October 1, 2014

Latest News

Meet us at ECCO!

January 5, 2018

Calpro press release regarding MSD agreement

Please see the Calpro press release regarding MDS agreement for delivery of e-health technology CalproSmart:

Norsk | English October 13, 2016

Calprosmart in the Media

Please see our latest articles regarding CalproSmart in Aftenposten and LMF Norge

LMF Norge | Aftenposten October 12, 2016

View all latest